免疫检查点抑制剂相关神经病的多样表型与管理
该研究描述了19例免疫检查点抑制剂(ICI)相关神经病(irNeuropathy)的谱系、临床过程和管理,并与细胞毒性药物所致神经病进行比较。irNeuropathy表现多样,常伴其他器官免疫相关不良事件,皮质类固醇治疗与改良Rankin量表评分和INCAT残疾评分改善相关。与化疗所致中毒性神经病相比,irNeuropathy更常表现为急性或亚急性、非长度依赖性,且住院率更高。
要点
- ICI相关神经病罕见(发生率0.7%),表型谱广泛,包括颅神经病、多神经根神经病等。
- 皮质类固醇治疗与神经病残疾评分改善相关(改良Rankin量表1 vs 0,p=0.001)。
- irNeuropathy较化疗所致神经病更常呈急性/亚急性非长度依赖性,住院率更高。
核心结论
- 神经病是ICI的罕见并发症,常对免疫抑制治疗有反应。
- 识别其广泛表型谱和独特临床特征并及时使用皮质类固醇可能带来良好结局。
研究设计与样本
- 研究纳入19例ICI相关神经病患者,并将其临床特征与细胞毒性药物所致神经病进行比较。
主要发现
- ICI包括抗PD1 9例、抗CTLA4 2例、抗CTLA4联合抗PD1 8例;神经病起病前ICI中位剂量为4次。
- 神经病表型包括颅神经病伴或不伴脑膜炎(n=7)、非长度依赖性多神经根神经病伴或不伴颅神经受累(n=6)、小纤维/自主神经病(n=2)等。
- 其他器官系统免疫相关不良事件常见(58%)。
- 皮质类固醇治疗与改良Rankin量表评分改善相关(1 vs 0,p=0.001),与INCAT残疾评分改善相关(2 vs 0.5,p=0.012)(Class IV)。
- 与化疗所致中毒性神经病相比,irNeuropathy急性或亚急性及非长度依赖性表现比例显著更高(p<0.001),住院率也更高(p=0.002)。
关键数值与推荐
- ICI相关神经病发生率为0.7%。
- 皮质类固醇治疗与改良Rankin量表评分改善相关(1 vs 0,p=0.001)。
- 皮质类固醇治疗与INCAT残疾评分改善相关(2 vs 0.5,p=0.012)。
临床怎么用
- 对接受ICI治疗的患者应警惕罕见但多样的神经病表现,尤其是急性或亚急性、非长度依赖性症状。
- 及时识别并使用皮质类固醇可能改善神经病结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the spectrum, clinical course, and management of neuropathies associated with immune checkpoint inhibitors (ICIs). METHODS: Patients with ICI-related neuropathy (irNeuropathy) were identified and their clinical characteristics compared to neuropathy attributed to cytotoxic agents. RESULTS: We identified 19 patients with irNeuropathies. ICIs included anti-programmed death-1 (PD1), 9; anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), 2; and combination of anti-CTLA4 and anti-PD1, 8. Median number of ICI doses prior to neuropathy onset was 4. Rate of neuropathies following ICI therapy was 0.7%. Underlying malignancies included melanoma (n = 15), lung adenocarcinoma (n = 3), and cholangiocarcinoma (n = 1). Neuropathy phenotypes were cranial neuropathies with or without meningitis (n = 7), nonlength-dependent polyradiculoneuropathies with and without cranial nerve involvement (n = 6), small-fiber/autonomic neuropathy (n = 2), ANCA-associated mononeuritis multiplex (n = 1), sensory neuronopathy (n = 1), length-dependent sensorimotor axonal polyneuropathy (n = 1), and neuralgic amyotrophy (n = 1). Immune-related adverse events involving other organ systems were common (58%). Corticosteroid use for management of neuropathy was associated with improvement in median modified Rankin Scale score (1 vs 0, p = 0.001) and Inflammatory Neuropathy Cause and Treatment Disability score (2 vs 0.5, p = 0.012) (Class IV). Significantly higher proportion of irNeuropathies had acute or subacute and nonlength-dependent presentations (p < 0.001) and rate of hospitalization for irNeuropathy was also higher (p = 0.002) compared to toxic neuropathy from chemotherapy. CONCLUSION: Neuropathy is a rare complication of ICIs that often responds to immunosuppression. Recognition of its wide phenotypic spectrum and distinct clinical characteristics and prompt management with corticosteroids may lead to favorable outcomes.
引用
- Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019. PMID: 31405908. doi:10.1212/WNL.0000000000008091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。